RxDoctor Payments Data

Daniel Hoffman, DO

Internal Medicine · Beverly Hills, CANPI 1437133394

Payments from drug & device makers

$7,358in general payments, 2019–2025

Across 318 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$949
  • Amgen$904
  • Pfizer$889
  • Boehringer Ingelheim$662
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$522
  • Lilly USA, LLC$466
  • plus $3K from 37 others

What the payments were for

  • Speaking & faculty fees$1502%
  • Food & beverage$7,20898%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,358 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$107,199
Medicare patients
216
Services billed
929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide55$54,520
OzempicSemaglutide21$19,917
EliquisApixaban18$12,576
Breo ElliptaFluticasone/Vilanterol25$8,801
JardianceEmpagliflozin14$8,348
TrulancePlecanatide14$7,684
LinzessLinaclotide11$5,676
LivaloPitavastatin Calcium12$5,629
PaxlovidNirmatrelvir/Ritonavir17$2,695
SynthroidLevothyroxine Sodium21$1,134
Atorvastatin Calcium147$1,082
Celecoxib12$841
Levothyroxine Sodium69$774
Albuterol Sulfate HfaAlbuterol Sulfate47$770
ValacyclovirValacyclovir Hcl21$757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$466$54,52055 claims
Novo NordiskOzempic$22$19,91721 claims
PfizerEliquis, Paxlovid$889$15,27135 claims
GSKBreo Ellipta$39$8,80125 claims
Boehringer IngelheimJardiance$662$8,34814 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$522$7,68414 claims
AbbVieLinzess, Synthroid$949$6,81032 claims
Kowa Pharmaceuticals America, Inc.Livalo$47$5,62912 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$75$77469 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →